Table 2.

Adjusted^a Analysis of Demographic and Clinical Characteristics Associated With Ever Having Been Prescribed an INSTI vs Never Having Been Prescribed an INSTI (n = 9558)^b

	Ever (n = 7442) vs Never (n = 1933) on an INSTI
	Adjusted OR (95% CI)
Clinic location
Baltimore—Hopkins	Ref
DC	1.97 (1.69–2.29)*
Age, y
18–24	2.15 (1.42–3.26)*
25–39	1.05 (0.90–1.22)
40–49	0.92 (0.80–1.06)
50+	Ref
Gender and sexual risk behavior
Cisgender male—MSM	Ref
Cisgender male—heterosexual	0.94 (0.82–1.07)
Cisgender female	1.02 (0.89–1.18)
Transgender female	0.62 (0.43–0.89)*
Transgender male	0.63 (0.16–2.51)
Race/ethnicity
Non-Hispanic White	Ref
Hispanic	1.22 (0.93–1.60)
NH Black	0.95 (0.81–1.12)
Other	0.74 (0.49–1.10)
Unknown	0.98 (0.67–1.43)
Insurance status
Public	Ref
Private	1.02 (0.90–1.15)
Other	0.88 (0.59–1.31)
Unknown	0.92 (0.67–1.27)
Current alcohol abuse	1.29 (1.12–1.47)*
HIV drug resistance mutations
Major NRTI mutation present (vs absent)	1.85 (1.50–2.27)*
Major NNRTI mutation present (vs absent)	1.50 (1.24–1.82)*
Major PI mutation present (vs absent)	1.25 (0.95–1.63)
Major INSTI mutation present (vs absent)	0.96 (0.60–1.55)
Years since first HIV care visit at clinic (per 5-y increase)b	0.98 (0.97–0.99)*

Abbreviations: IDU, injection drug use; INSTI, integrase strand transfer inhibitor; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor.

*P < .05.

^aAnalysis adjusted for all factors shown in Table 2 plus the following defined in Supplementary Table 1: chronic hepatitis B, chronic hepatitis C, diabetes, chronic kidney disease, and the following: last recorded and nadir CD4 count, current smoking, history of IDU, and last recorded HIV RNA level.

^bThere were 183 participants in the DC Cohort who had missing values for years since first HIV care visit at the clinic and were excluded from the adjusted analysis.